ThromboVision’s New Director of Engineering


ThromboVision’s New Director of Engineering

Brings Biotech and Design Background

HOUSTON, April 2008 ----- ThromboVision, Inc., a Houston-based biomedical diagnostics company, has appointed Alberto (Albert) Rodriguez to be director of engineering.

Rodriguez will manage final design of ThromboVision’s ThromboGuide® (T-Guide®) Platelet Function Monitor, continue building the engineering/manufacturing team, and oversee the ramp-up of manufacturing when clinical trials are complete.

Rodriguez comes to ThromboVision from Cyberonics, where he served most recently as senior manager of design engineering. He brings experience with product and technology development, regulatory audits, software development, and strategic planning to support the research and clinical phases prior to market release.

“ThromboVision sought an engineering director who could both motivate our manufacturing team and prepare the T-Guide for the critical come-to-market phase, and Albert brings that combination of leadership and technical skills,” said Dr. Edward R. Teitel, ThromboVision president and CEO.

Earlier in his career, Rodriguez worked with McDonnell Douglas/Boeing on communication satellite software and control systems. He holds a BS in computer science from the University of Houston–Clear Lake, is pursuing PMP certification from the Project Management Institute, and is active in the Association for the Advancement of Medical Instrumentation.


ThromboVision, Inc.,, is a biomedical company committed to enabling people to lead longer and healthier lives. ThromboVision provides easy-to-use, rapid-response, cost-effective, and versatile point-of-care clinical diagnostic discoveries that advance medical diagnosis. The company’s products will improve medical care by assisting physicians in diagnosing and managing critical cardiovascular risk factors, especially those related to platelet function and antiplatelet drug therapy.

ThromboVision is a Houston Technology Center (HTC) client company.  HTC is a business accelerator that assists Houston-based emerging technology companies in key sectors such as Energy, Information Technology, Life Sciences, Nanotechnology and NASA-originated technologies.



This release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Statements in this release regarding ThromboVision’s business that are not historical facts are “forward-looking statements,” which involve risks and uncertainties that could cause actual results to differ materially from any future results, performance, or achievements expressed or implied by such statements.



Author: Edward R. Teitel, M.D.
Phone: (713) 491-4449
Category: client companies | Sub Category: life sciences